A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder

被引：0
作者：
Heather Y. F. Yong
Jodie M. Burton
机构：
[1] University of Calgary,Division of Neurology, Department of Clinical Neurosciences
[2] Cummings School of Medicine,Department of Community Health Sciences
[3] University of Calgary,Hotchkiss Brain Institute
[4] University of Calgary,undefined
来源：
Current Neurology and Neuroscience Reports | 2023年 / 23卷
关键词：
Neuromyelitis optica spectrum disorder; NMO; NMOSD; Disease-modifying therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：489 / 506
页数：17
相关论文
共 955 条
  • [1] Papp V(2021)Worldwide incidence and prevalence of neuromyelitis optica: a systematic review Neurology 96 59-77
  • [2] Magyari M(2020)Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide Front Neurol 11 501-418
  • [3] Aktas O(2019)Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models Mult Scler Relat Disord 27 412-2112
  • [4] Berger T(2019)Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence Neurol Neuroimmunol Neuroinflamm. 7 16727-477
  • [5] Broadley SA(2020)Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis Sci Rep 10 2106-544
  • [6] Cabre P(2004)A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis Lancet 364 473-2094
  • [7] Hor JY(2005)IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel J Exp Med 202 535-72
  • [8] Asgari N(2012)Aquaporin 4 and neuromyelitis optica Lancet Neurol 11 2088-250
  • [9] Nakashima I(2017)What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients J Neurol 264 66-374
  • [10] Broadley SA(2018)MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder Mult Scler Relat Disord 25 239-66
12345678910